NetworkNewsBreaks – Multiverse Investment Fund’s Orbsen Therapeutics to Initiate Clinical Trials to Treat ARDS Caused by COVID-19

April 15, 2020 09:53:44

Addressing the finding that most COVID-19 fatalities are caused by the nonreversible development of acute respiratory distress syndrome (“ARDS”), Multiverse Investment Fund today announced that one of its 12 portfolio companies, Orbsen Therapeutics, was awarded a special dispensation by the government of England to initiate clinical trials of its proprietary cellular therapy, ORBCEL, to treat ARDS patients diagnosed with COVID-19. Jack Kavanaugh, a general manager of Multiverse Investment Fund, a private venture capital fund dedicated to long-term capital investment in companies offering significant social impact, and chairman of Orbsen Therapeutics, stated, “We are incredibly proud of Orbsen’s achievements and the team’s involvement in working to expedite solutions to help prevent deaths from COVID-19.”

To view the full press release, visit

About Multiverse Investment Fund

Multiverse Investment Fund I, LP is a private venture capital fund that invests in early-, developmental- and clinical-stage companies in the life science, materials science and technology sectors. Multiverse’s mission is to achieve long-term capital appreciation through investments in profound opportunities and, as a general proposition, in companies building products with the potential to produce a positive and significant social impact. For more information, visit the company’s website at

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.